China's Walvax conducts large mRNA Covid vaccine trial
ReutersChina's Walvax Biotechnology has recruited most of the 28,000 participants needed for a large clinical trial of its mRNA COVID-19 vaccine candidate, a senior company official said on Thursday.
China has yet to approve a Chinese vaccine of the novel messenger RNA (mRNA) technology and has yet to import a foreign mRNA vaccine.
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable
